PRospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With ChemoradIotherapy Followed by cONsolidation Therapy With Durvalumab (PRECISION)

Conditions:   Oncology;   Biomarker;   NSCLC, Stage III;   Durvalumab;   Chemoradiotherapy Intervention:   Other: Non-interventional Sponsors:   LMU Klinikum;   Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany;   Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany;   Asklepios Lung Clinic, Munich-Gauting, Germany;   Department of Radiology, University Hospital, LMU Munich, Munich, Germany;   Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany;   Institute for Medical Information Processing, Biometry and Epidemiology, LMU München, Munich, Germany;   Department of Medicine II, University Hospital, LMU Munich, Munich, Germany;   Immunoanalytics Research Group Tissue Control of Immunocytes, Helmholtz Center Munich, Munich, Germany Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials